Login to Your Account



Celgene to present promising data on Crohn's therapy

By Peter Winter
BioWorld Insight Editor

Monday, October 20, 2014
When Celgene Corp. reported that it was shelling out a whopping $710 million up front to little known privately held Nogra Pharma Ltd. to develop and commercialize GED-0301, an oral antisense DNA oligonucleotide targeting Smad7 mRNA for the treatment of moderate to severe Crohn's disease (CD), eyebrows were raised by analysts who follow the company.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription